BHV-1300 for adults with Graves' disease, looking at safety and markers
Tests BHV-1300 for safety in adults with Graves' disease.
Key facts
- Who runs it
- Biohaven Therapeutics Ltd.
- Where
- Canton, Columbus, Dallas, Greenville, Houston, Memphis, Miami, Shavano Park, and South Gate, United StatesSee the 10 sitesAlso in 1 other country, 8 sites
- Trial code
- Registry title
- Study of BHV-1300 in Graves' Disease
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Started
- 21 Aug 2025
- Expected to end
- Sept 2027
- Type of study
- Interventional
- Treatments tested
- BHV-1300
- Record updated
- 31 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves' disease, an immune condition that makes the thyroid overactive. It tests whether BHV-1300 is safe and how it affects disease markers.
- Age
- 18 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- Graves' disease confirmed by a blood test.
- Earlier treatment
- People who have had radioactive iodine treatment or thyroid surgery cannot join.
- Biomarker or test result
- Graves' disease must be confirmed by a blood test (serologically confirmed).
Main reasons for not taking part
- Overactive thyroid caused by something other than Graves' disease, such as toxic adenoma or toxic multinodular goiter
- Thyroid storm (a sudden, severe flare of overactive thyroid) within six weeks of the Baseline visit
- Past radioactive iodine treatment
- Past thyroid surgery
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Participants must have serologically confirmed Graves' Disease
Who cannot take part
- History of treatment with radioactive iodine or thyroid surgery
- History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
Also in 1 other country, 8 sites
- Canton, OhioHospital not named in the registryContact: Chief Medical OfficerTaking people
- Columbus, GeorgiaHospital not named in the registryContact: Chief Medical OfficerTaking people
- Dallas, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
- Greenville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
- Houston, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
- Houston, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
- Memphis, TennesseeHospital not named in the registryContact: Chief Medical OfficerTaking people
- Miami, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
- Shavano Park, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
- South Gate, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
The group in the trial
- BHV-1300Treatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
- Plain-language title
- BHV-1300 for adults with Graves' disease, looking at safety and markersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06980649, who can take part
- Record updated
- 31 July 2026